RxDoctor Payments Data

Steven Carlson

Clinical Cardiac Electrophysiology · Chula Vista, CANPI 1467602946

Payments from drug & device makers

$49,295in general payments, 2019–2025

Across 727 payments — averaging $67.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$16K
  • Medical Device Business Services, Inc.$11K
  • Boston Scientific$7K
  • Biosense Webster, Inc.$5K
  • Medtronic$2K
  • Biotronik Inc.$1K
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$19,08239%
  • Travel & lodging$2,3755%
  • Food & beverage$27,52556%
  • Education$3141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,295 in reported general payments places this provider in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$464,848
Medicare patients
784
Services billed
4,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$244,765
XareltoRivaroxaban108$111,957
EntrestoSacubitril/Valsartan29$25,942
MultaqDronedarone Hcl15$22,730
Flecainide Acetate99$2,998
Metoprolol Succinate206$2,780
Midodrine Hcl16$1,564
Amiodarone Hcl62$1,104
Losartan Potassium78$640
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$627
Diltiazem 12hr ErDiltiazem Hcl11$579
Metoprolol Tartrate118$571
Bumetanide13$553
Carvedilol83$540
Propranolol Hcl19$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$224$244,765227 claims
Johnson & JohnsonXarelto$728$111,957108 claims
NovartisEntresto$90$25,94229 claims
Sanofi-aventis U.S. LLCMultaq$54$22,73015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →